The findings of the first study suggest that the antivirals are unlikely to contribute to viral rebound and to spread in the community under current conditions, the authors say.
COVID antiviral studies: Emergent resistance mutations rare, Paxlovid awareness low
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- US flu season shows signs of peak
- Hospitalized COVID patients at higher risk for organ-related death, readmission for 2.5 years, data suggest
- Liberals’, conservatives’ trust in US government’s use of digital health data diverged during COVID
- Report: COVID survivors nearly twice as likely to have ongoing symptoms as those with flu